NASDAQ:AIMT - Aimmune Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $22.93 -0.27 (-1.16 %) (As of 02/22/2019 06:00 AM ET)Previous Close$23.20Today's Range$22.67 - $23.5452-Week Range$21.22 - $37.81Volume480,562 shsAverage Volume552,824 shsMarket Capitalization$1.35 billionP/E RatioN/ADividend YieldN/ABeta-0.12 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. The company has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California. Receive AIMT News and Ratings via Email Sign-up to receive the latest news and ratings for AIMT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AIMT Previous Symbol CUSIPN/A CIK1631650 Webwww.aimmune.com Phone650-614-5220Debt Debt-to-Equity RatioN/A Current Ratio6.99 Quick Ratio6.99Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.50 per share Price / Book6.55Profitability EPS (Most Recent Fiscal Year)($2.61) Net Income$-131,320,000.00 Net MarginsN/A Return on Equity-74.83% Return on Assets-65.91%Miscellaneous Employees131 Outstanding Shares58,730,000Market Cap$1.35 billion Next Earnings Date3/11/2019 (Estimated) OptionableOptionable Aimmune Therapeutics (NASDAQ:AIMT) Frequently Asked Questions What is Aimmune Therapeutics' stock symbol? Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT." How were Aimmune Therapeutics' earnings last quarter? Aimmune Therapeutics Inc (NASDAQ:AIMT) released its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.92) by $0.03. View Aimmune Therapeutics' Earnings History. When is Aimmune Therapeutics' next earnings date? Aimmune Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for Aimmune Therapeutics. What price target have analysts set for AIMT? 8 Wall Street analysts have issued 12-month price objectives for Aimmune Therapeutics' shares. Their predictions range from $30.01 to $80.00. On average, they anticipate Aimmune Therapeutics' share price to reach $53.1263 in the next year. This suggests a possible upside of 131.7% from the stock's current price. View Analyst Price Targets for Aimmune Therapeutics. What is the consensus analysts' recommendation for Aimmune Therapeutics? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aimmune Therapeutics in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aimmune Therapeutics. What are Wall Street analysts saying about Aimmune Therapeutics stock? Here are some recent quotes from research analysts about Aimmune Therapeutics stock: 1. According to Zacks Investment Research, "Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. " (2/4/2019) 2. Cantor Fitzgerald analysts commented, ". We are assuming coverage of AIMT with an Overweight rating and a 12-month PT of $64 based on lead asset AR101 in peanut allergy. Given the growing unmet clinical need in PA, ‘101 has Track designations, and we believe a high regulatory PoS exists based on data from the P3 PALISADE study. Full study data were recently published in the NEJM, validating the results and further enhancing our conviction given the notably reduced use of rescue epinephrine during the DBPCFC and limited use during updosing." (12/2/2018) Has Aimmune Therapeutics been receiving favorable news coverage? Media coverage about AIMT stock has been trending positive on Friday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aimmune Therapeutics earned a news impact score of 2.3 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an effect on the stock's share price in the next few days. Who are some of Aimmune Therapeutics' key competitors? Some companies that are related to Aimmune Therapeutics include Alkermes (ALKS), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR), Array Biopharma (ARRY), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), TESARO (TSRO), Taro Pharmaceutical Industries (TARO), Amneal Pharmaceuticals (AMRX), Horizon Pharma (HZNP), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Blueprint Medicines (BPMC), Agios Pharmaceuticals (AGIO) and Emergent Biosolutions (EBS). What other stocks do shareholders of Aimmune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aimmune Therapeutics investors own include Hawkins (HWKN), Alibaba Group (BABA), Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Micron Technology (MU), Exelixis (EXEL), CA (CA), Canopy Growth (CGC), AbbVie (ABBV) and Sarepta Therapeutics (SRPT). Who are Aimmune Therapeutics' key executives? Aimmune Therapeutics' management team includes the folowing people: Mr. Eric H. Bjerkholt, Chief Financial Officer (Age 59)Mr. Jeffrey H. Knapp, Chief Operating Officer (Age 53)Mr. Douglas T. Sheehy, Gen. Counsel & Sec. (Age 52)Dr. Daniel C. Adelman, Chief Medical Officer (Age 62)Dr. Jayson Donald Alexander Dallas, Pres, CEO & Director (Age 51) When did Aimmune Therapeutics IPO? (AIMT) raised $124 million in an initial public offering (IPO) on Thursday, August 6th 2015. The company issued 8,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray served as the underwriters for the IPO. Who are Aimmune Therapeutics' major shareholders? Aimmune Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.34%), Foresite Capital Management II LLC (5.05%), Eagle Asset Management Inc. (2.24%), Victory Capital Management Inc. (1.62%), Emerald Advisers LLC (1.26%) and Foresite Capital Management III LLC (1.21%). Company insiders that own Aimmune Therapeutics stock include Bakker Juliet Tammenoms, Daniel C Md Adelman, Douglas T Sheehy, Eric Bjerkholt, Jayson Donald Alexander Dallas, Kathryn E Falberg, Mary M Rozenman, Patrick G Enright, Stephen George Dilly, Susan E Barrowcliffe and Warren L Desouza. View Institutional Ownership Trends for Aimmune Therapeutics. Which institutional investors are selling Aimmune Therapeutics stock? AIMT stock was sold by a variety of institutional investors in the last quarter, including Foresite Capital Management II LLC, BlackRock Inc., Foresite Capital Management III LLC, Barclays PLC, Jennison Associates LLC, RMB Capital Management LLC, Eagle Asset Management Inc. and Taylor Wealth Management Partners. Company insiders that have sold Aimmune Therapeutics company stock in the last year include Douglas T Sheehy, Mary M Rozenman and Stephen George Dilly. View Insider Buying and Selling for Aimmune Therapeutics. Which institutional investors are buying Aimmune Therapeutics stock? AIMT stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Emerald Advisers LLC, Victory Capital Management Inc., Emerald Mutual Fund Advisers Trust, Opaleye Management Inc., SG Americas Securities LLC, Massachusetts Financial Services Co. MA and Hudson Bay Capital Management LP. Company insiders that have bought Aimmune Therapeutics stock in the last two years include Bakker Juliet Tammenoms, Eric Bjerkholt, Jayson Donald Alexander Dallas, Kathryn E Falberg and Patrick G Enright. View Insider Buying and Selling for Aimmune Therapeutics. How do I buy shares of Aimmune Therapeutics? Shares of AIMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Aimmune Therapeutics' stock price today? One share of AIMT stock can currently be purchased for approximately $22.93. How big of a company is Aimmune Therapeutics? Aimmune Therapeutics has a market capitalization of $1.35 billion. The biotechnology company earns $-131,320,000.00 in net income (profit) each year or ($2.61) on an earnings per share basis. Aimmune Therapeutics employs 131 workers across the globe. What is Aimmune Therapeutics' official website? The official website for Aimmune Therapeutics is http://www.aimmune.com. How can I contact Aimmune Therapeutics? Aimmune Therapeutics' mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-614-5220 or via email at [email protected] MarketBeat Community Rating for Aimmune Therapeutics (NASDAQ AIMT)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 318 (Vote Outperform)Underperform Votes: 209 (Vote Underperform)Total Votes: 527MarketBeat's community ratings are surveys of what our community members think about Aimmune Therapeutics and other stocks. Vote "Outperform" if you believe AIMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AIMT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/22/2019 by MarketBeat.com StaffFeatured Article: What is the yield curve?